Novartis Aktie
WKN: 904278 / ISIN: CH0012005267
|
24.04.2026 07:14:44
|
Press Release: Novartis malaria treatment -2-
Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.
References
1. WHO. What We Do | WHO - Prequalification of Medical Products (IVDs,
Medicines, Vaccines and Immunization Devices, Vector Control)
https://extranet.who.int/prequal/about/what-we-do ; Prequalification of
medicines by WHO
https://www.who.int/news-room/fact-sheets/detail/prequalification-of-medicines-by-who
[Last Accessed: April 2026]
2. WHO (2025). World malaria report 2025
https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025
[Last Accessed: April 2026]
3. D'Alessandro U, et al. Malaria in infants aged less than six months - is
it an area of unmet medical need? Malar J. 2012 Dec 2;11:400. doi:
10.1186/1475-2875-11-400. PMID: 23198986; PMCID: PMC3529680.
4. Dobbs, et al. Plasmodium malaria and antimalarial antibodies in the first
year of life. Parasitology. 2016;143(2):129-138.
doi:10.1017/S0031182015001626
5. Reddy, Valentina et al. Global estimates of the number of pregnancies at
risk of malaria from 2007 to 2020: a demographic study. The Lancet Global
Health, Volume 11, Issue 1, e40 - e47
6. Ceesay SJ et al. Malaria Prevalence among Young Infants in Different
Transmission Settings, Africa. Emerg Infect Dis. 2015 Jul;21(7):1114-21.
doi: 10.3201/eid2107.142036. PMID: 26079062; PMCID: PMC4480393.
7. Access to Medicine Foundation (2024). Access to Medicine Index 2024 [Last
Accessed April 2026].
# # #
Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
(END) Dow Jones Newswires
April 24, 2026 01:15 ET (05:15 GMT)
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AG
|
24.04.26 |
Schwacher Handel: STOXX 50 verbucht zum Handelsende Verluste (finanzen.at) | |
|
24.04.26 |
Schwacher Handel in Zürich: SLI zeigt sich letztendlich schwächer (finanzen.at) | |
|
24.04.26 |
Minuszeichen in Zürich: SMI beendet die Sitzung weit in der Verlustzone (finanzen.at) | |
|
24.04.26 |
Handel in Europa: STOXX 50 zeigt sich nachmittags schwächer (finanzen.at) | |
|
24.04.26 |
Schwacher Wochentag in Zürich: SMI schwächelt am Nachmittag (finanzen.at) | |
|
24.04.26 |
Schwacher Handel in Zürich: SLI nachmittags leichter (finanzen.at) | |
|
24.04.26 |
Press Release: Novartis receives positive CHMP -2- (Dow Jones) | |
|
24.04.26 |
Press Release: Novartis receives positive CHMP opinion for Itvisma(R) for spinal muscular atrophy (SMA) (Dow Jones) |
Analysen zu Novartis AG
| 10.04.26 | Novartis Neutral | UBS AG | |
| 31.03.26 | Novartis Sell | Goldman Sachs Group Inc. | |
| 30.03.26 | Novartis Buy | Deutsche Bank AG | |
| 27.03.26 | Novartis Equal Weight | Barclays Capital | |
| 24.03.26 | Novartis Buy | Deutsche Bank AG |
Aktien in diesem Artikel
| Novartis AG (Spons. ADRS) | 124,00 | -1,59% |
|
| Novartis AG | 122,66 | -2,88% |
|